<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ir J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Ir J Med Sci</journal-id><journal-title-group><journal-title>Irish Journal of Medical Science</journal-title></journal-title-group><issn pub-type="ppub">0021-1265</issn><issn pub-type="epub">1863-4362</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39821068</article-id><article-id pub-id-type="pmc">PMC11861129</article-id>
<article-id pub-id-type="publisher-id">3864</article-id><article-id pub-id-type="doi">10.1007/s11845-024-03864-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Redefining cancer care: the importance of primary care cancer research in Ireland</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0008-4669-9765</contrib-id><name><surname>O&#x02019;Regan</surname><given-names>Sean</given-names></name><address><email>seanoregan20@rcsi.ie</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0009-0586-7758</contrib-id><name><surname>Adams</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1119-064X</contrib-id><name><surname>Jacob</surname><given-names>Benjamin M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3686-3898</contrib-id><name><surname>Burns</surname><given-names>Heather</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3929-2018</contrib-id><name><surname>Redmond</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01hxy9878</institution-id><institution-id institution-id-type="GRID">grid.4912.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0488 7120</institution-id><institution>Department of General Practice, </institution><institution>RCSI, </institution></institution-wrap>Dublin, Ireland </aff><aff id="Aff2"><label>2</label>HSE National Cancer Control Programme, Dublin, Ireland </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>194</volume><issue>1</issue><fpage>55</fpage><lpage>58</lpage><history><date date-type="received"><day>5</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer survivors</kwd><kwd>Early detection of cancer</kwd><kwd>Health services accessibility</kwd><kwd>Ireland</kwd><kwd>Neoplasms (cancer)</kwd><kwd>Primary health care</kwd></kwd-group><funding-group><award-group><funding-source><institution>Royal College of Surgeons in Ireland (RCSI)</institution></funding-source></award-group><open-access><p>Open Access funding provided by the IReL Consortium</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Royal Academy of Medicine in Ireland 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Cancer is a significant public health challenge</title><p id="Par1">Cancer represents a significant public health challenge in Ireland. As of 2022, nearly a third of all deaths were attributed to invasive malignancies [<xref ref-type="bibr" rid="CR1">1</xref>]. Moreover, one in every two people in Ireland will develop invasive cancer (excluding non-melanoma skin cancer) in their lifetime [<xref ref-type="bibr" rid="CR2">2</xref>]. Forecasts also indicate a potential doubling of cancer diagnoses between 2010 and 2040, primarily due to an ageing population [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par2">Despite these stark statistics, the past three decades have seen Ireland make significant advancements in cancer care, guided by three successive national cancer strategies [<xref ref-type="bibr" rid="CR1">1</xref>]. These have contributed to reduced mortality rates for the most prevalent cancers and an increase in 5-year age-standardised cancer survival rates from 42 to 65% over a twenty-year period [<xref ref-type="bibr" rid="CR4">4</xref>]. Despite these achievements, Ireland&#x02019;s age-standardised incidence and mortality rates remain amongst the highest within the OECD (Organisation for Economic Co-Operation and Development) [<xref ref-type="bibr" rid="CR5">5</xref>]. This indicates a need for continued innovation in our approach to cancer control.</p></sec><sec id="Sec2"><title>Shifting the focus to primary care: prevention and early diagnosis</title><p id="Par3">In recent years, there has been a shift in cancer control strategies towards prioritising prevention and early diagnosis, as the most cost-effective long-term approach to cancer control [<xref ref-type="bibr" rid="CR6">6</xref>]. The National Cancer Strategy (2017&#x02013;2026) advocates for robust public education, risk reduction, and early detection programmes, primarily managed within primary care [<xref ref-type="bibr" rid="CR1">1</xref>]. Simultaneously, there is a global trend towards bolstering primary care as the cornerstone of healthcare due to its accessibility, cost-effectiveness, and preference amongst patients for receiving care closer to home [<xref ref-type="bibr" rid="CR7">7</xref>]. Reflecting this trend, Ireland&#x02019;s Sl&#x000e1;intecare Programme aims to revolutionise health and social care services by expanding community and primary care infrastructure [<xref ref-type="bibr" rid="CR8">8</xref>]. Equally, the National Cancer Strategy explicitly calls for an expanded role for general practitioners (GPs) in managing the entire cancer continuum, from prevention and early diagnosis to treatment and ongoing survivor support [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="Sec3"><title>Primary care research and the future</title><p id="Par4">Despite its increasing importance in cancer control, primary care research has historically received less funding compared to laboratory and hospital-based research [<xref ref-type="bibr" rid="CR9">9</xref>]. From 2016 to 2020, global cancer research funding heavily favoured cancer biology (45%) and drug treatment (20%), with primary care-related themes like diagnosis, screening, monitoring, psychosocial aspects, and survivorship receiving just 15% of total awards [<xref ref-type="bibr" rid="CR10">10</xref>]. This funding imbalance has contributed to considerable gaps in primary care knowledge and practise.</p><p id="Par5">Addressing these gaps is crucial, and a national research group dedicated to primary care cancer research could be a pivotal step. Such an entity could streamline research efforts, foster meaningful collaborations, and minimise work duplication, thereby supporting researchers to address critical knowledge gaps.</p><p id="Par6">Internationally, this collaborative approach has shown success. Australia&#x02019;s Primary Care Collaborative Cancer Clinical Trials Group (PC4), The Cancer and Primary Care Research International Network (Ca-PRI), and the UK&#x02019;s CanTest Collaborative are prime examples of how collaborative efforts can substantially contribute to the field. These groups have successfully bridged the gap between researchers, healthcare practitioners, policymakers, and patients, leading to significant advancements.</p><p id="Par7">In Ireland, a similar momentum is gathering with the formation of a stakeholder group for primary care-focused cancer research [<xref ref-type="bibr" rid="CR11">11</xref>]. Mobilising existing resources and talent towards a unified research strategy could support enhanced cancer control in Ireland.</p><sec id="Sec4"><title>Examples of current research questions</title><p id="Par8">The following are examples of primary care research questions which could address existing knowledge gaps in the Irish context.</p></sec><sec id="Sec5"><title>Prevention</title><p id="Par9">Modifiable factors account for 30&#x02013;50% of cancer incidence [<xref ref-type="bibr" rid="CR12">12</xref>], and with over 90% of the Irish population visiting their GP annually [<xref ref-type="bibr" rid="CR13">13</xref>], primary care can significantly impact cancer prevention. The &#x02018;Making Every Contact Count&#x02019; (MECC) framework encourages GPs to guide patients towards healthier lifestyles [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the content, frequency, and effectiveness of these brief interventions in Ireland is unclear. Future research should focus on understanding these interventions, identifying barriers, and exploring ways to enhance the impact of preventative advice.</p></sec><sec id="Sec6"><title>Early detection</title><p id="Par10">Early detection of cancer is a key first step towards achieving higher survival rates, reducing treatment severity, and improving quality of life for people living with cancer [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Whilst screening enables early detection of some presymptomatic cancer, approximately 85% of cancers are diagnosed after the onset of symptoms [<xref ref-type="bibr" rid="CR6">6</xref>]. This fact underscores the importance of equipping primary care with robust clinical guidelines and efficient referral pathways. The National Cancer Control Programme&#x02019;s Rapid Access Clinics (RACs) [<xref ref-type="bibr" rid="CR16">16</xref>] represent a significant step in this direction. A comprehensive analysis of RAC referrals, including demographic and clinical profiles, is crucial to understand and optimise their utilisation.</p></sec><sec id="Sec7"><title>Screening</title><p id="Par11">Screening plays a critical role in reducing cancer incidence and mortality by detecting and treating pre-cancerous conditions and asymptomatic early-stage cancers. However, the uptake of cancer screening in Ireland is inconsistent, influenced significantly by sociodemographic factors [<xref ref-type="bibr" rid="CR1">1</xref>]. Research into the barriers and attitudes towards cancer screening in Ireland is essential to develop targeted strategies for improving uptake, particularly amongst high-risk groups. Whilst studies pertaining to certain screening programmes, such as the cervical cancer screening programme [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], have been conducted, more comprehensive research across various cancer types is needed.</p></sec><sec id="Sec8"><title>Survivorship</title><p id="Par12">The number of cancer survivors has grown by 50% in the past decade with approximately 215,000 cancer patients or former cancer patients alive as of 2021, equivalent to 4.3% of the population [<xref ref-type="bibr" rid="CR19">19</xref>]. This growth challenges the sustainability of the traditional hospital-centred follow-up model, signalling a shift towards primary care-led survivorship care [<xref ref-type="bibr" rid="CR6">6</xref>]. Whilst research has been undertaken into the survivorship needs of patients with common cancers, such as prostate cancer, the needs of those with other diagnoses, such as melanoma, testicular, and bladder cancer, have been less comprehensively explored [<xref ref-type="bibr" rid="CR20">20</xref>]. Further research in these areas is vital to develop evidence-based initiatives addressing the needs of this expanding survivor population.</p></sec></sec><sec id="Sec9"><title>Emerging technologies and strategies</title><p id="Par13">The future of primary care cancer research extends beyond the current scope to include emerging technologies that necessitate translational research for clinical application. Notable examples of emerging technologies with implications for primary care include artificial intelligence (AI) models for lung cancer risk stratification using low-dose computed tomography (LDCT) [<xref ref-type="bibr" rid="CR21">21</xref>], multi-cancer screening through cell-free DNA (cfDNA) tests [<xref ref-type="bibr" rid="CR22">22</xref>], and personalised medicine approaches as highlighted in Ireland&#x02019;s National Strategy for Genetic and Genomic Medicine and the Hereditary Cancer Model of Care [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. These advancements represent a frontier in cancer diagnosis and treatment, requiring a focused strategy to translate them from research into clinical practise effectively.</p></sec><sec id="Sec10"><title>Conclusion</title><p id="Par14">As the landscape of cancer care evolves both in Ireland and globally, it presents both challenges and opportunities. The anticipated rise in cancer incidence demands proactive measures to strengthen the Irish healthcare system. By recognising the critical role of primary care across the cancer care continuum, and adopting a strategic approach to investment in research, Ireland can develop and implement evidence-based policies and strategies. This approach will not only mitigate the impacts of increasing cancer incidence but also position Ireland at the forefront of innovative and effective cancer care.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are grateful to Carmel Geoghegan, Stakeholder Group for Primary Care Research into Cancer (SPARC) for the PPI input.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided by the IReL Consortium</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par15">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethics</title><p id="Par16">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Department of Health (2017) National cancer strategy 2017 - 2026. <ext-link ext-link-type="uri" xlink:href="https://www.gov.ie/en/publication/a89819-national-cancer-strategy-2017-2026/">https://www.gov.ie/en/publication/a89819-national-cancer-strategy-2017-2026/</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Central Statistics Office (2023) Vital statistics yearly summary 2022 - CSO - Central Statistics Office. <ext-link ext-link-type="uri" xlink:href="https://www.cso.ie/en/releasesandpublications/ep/p-vsys/vitalstatisticsyearlysummary2022/">https://www.cso.ie/en/releasesandpublications/ep/p-vsys/vitalstatisticsyearlysummary2022/</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">National Cancer Registry (2014) Cancer projections for Ireland 2015&#x02013;2040. <ext-link ext-link-type="uri" xlink:href="https://www.ncri.ie/sites/ncri/files/pubs/Cancer%20projections%20for%20Ireland%202015%20-%202040.pdf">https://www.ncri.ie/sites/ncri/files/pubs/Cancer%20projections%20for%20Ireland%202015%20-%202040.pdf</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">National Cancer Registry Ireland (2021) Cancer in Ireland 1994&#x02013;2019: annual report of the National Cancer Registry. <ext-link ext-link-type="uri" xlink:href="https://www.ncri.ie/sites/ncri/files/pubs/NCRI_Annual%20Report_2021.pdf">https://www.ncri.ie/sites/ncri/files/pubs/NCRI_Annual%20Report_2021.pdf</ext-link></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">OECD (2021) Health at a Glance 2021: OECD Indicators. OECD</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>G</given-names></name><name><surname>Berendsen</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>SM</given-names></name><etal/></person-group><article-title>The expanding role of primary care in cancer control</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><fpage>1231</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00205-3</pub-id><pub-id pub-id-type="pmid">26431866</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Rubin G, Berendsen A, Crawford SM et al (2015) The expanding role of primary care in cancer control. Lancet Oncol 16:1231&#x02013;1272. 10.1016/S1470-2045(15)00205-3<pub-id pub-id-type="pmid">26431866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">World Health Organisation (2018) Declaration of Astana. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail-redirect/WHO-HIS-SDS-2018.61">https://www.who.int/publications-detail-redirect/WHO-HIS-SDS-2018.61</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Department of Health (2021) Sl&#x000e1;intecare Implementation Strategy &#x00026; Action Plan 2021&#x02013;2023. <ext-link ext-link-type="uri" xlink:href="https://www.gov.ie/pdf/?file=https://assets.gov.ie/134746/9b3b6ae9-2d64-4f87-8748-cda27d3193f3.pdf#page=null">https://www.gov.ie/pdf/?file=https://assets.gov.ie/134746/9b3b6ae9-2d64-4f87-8748-cda27d3193f3.pdf#page=null</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>B</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>L</given-names></name><name><surname>Clyne</surname><given-names>B</given-names></name><etal/></person-group><article-title>Early cancer detection in primary care in Ireland: a protocol for a research prioritisation exercise</article-title><source>HRB Open Res</source><year>2023</year><volume>6</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.12688/hrbopenres.13749.1</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Jacob B, O&#x02019;Connor L, Clyne B et al (2023) Early cancer detection in primary care in Ireland: a protocol for a research prioritisation exercise. HRB Open Res 6:52. 10.12688/hrbopenres.13749.1</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>SA</given-names></name><name><surname>Alam</surname><given-names>F</given-names></name><name><surname>Adams</surname><given-names>L</given-names></name><etal/></person-group><article-title>Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments</article-title><source>Lancet Oncol</source><year>2023</year><volume>24</volume><fpage>636</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(23)00182-1</pub-id><pub-id pub-id-type="pmid">37269844</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">McIntosh SA, Alam F, Adams L et al (2023) Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol 24:636&#x02013;645. 10.1016/S1470-2045(23)00182-1<pub-id pub-id-type="pmid">37269844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>B</given-names></name><name><surname>Burns</surname><given-names>H</given-names></name><name><surname>Chong</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Protocol for Establishing a stakeholder group for primary care research into cancer using a modified 7P framework and an e-Delphi process</article-title><source>HRB Open Res</source><year>2023</year><volume>6</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.12688/hrbopenres.13750.2</pub-id><pub-id pub-id-type="pmid">38283946</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jacob B, Burns H, Chong MC et al (2023) Protocol for Establishing a stakeholder group for primary care research into cancer using a modified 7P framework and an e-Delphi process. HRB Open Res 6:53. 10.12688/hrbopenres.13750.2<pub-id pub-id-type="pmid">38283946</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Arem</surname><given-names>H</given-names></name><name><surname>Loftfield</surname><given-names>E</given-names></name></person-group><article-title>Cancer epidemiology: a survey of modifiable risk factors for prevention and survivorship</article-title><source>Am J Lifestyle Med</source><year>2017</year><volume>12</volume><fpage>200</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1177/1559827617700600</pub-id><pub-id pub-id-type="pmid">30202392</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Arem H, Loftfield E (2017) Cancer epidemiology: a survey of modifiable risk factors for prevention and survivorship. Am J Lifestyle Med 12:200&#x02013;210. 10.1177/1559827617700600<pub-id pub-id-type="pmid">30202392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Health Service Executive (2016) Making every contact count: a health behaviour change framework and implementation plan for health professionals in the Irish health service. <ext-link ext-link-type="uri" xlink:href="https://www.hse.ie/eng/about/who/healthwellbeing/making-every-contact-count/making-every-contact-count-framework.pdf">https://www.hse.ie/eng/about/who/healthwellbeing/making-every-contact-count/making-every-contact-count-framework.pdf</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Crosby</surname><given-names>D</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Brindle</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Early detection of cancer</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>9040</fpage><pub-id pub-id-type="doi">10.1126/science.aay9040</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Crosby D, Bhatia S, Brindle KM et al (2022) Early detection of cancer. Science 375:9040. 10.1126/science.aay9040</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>W</given-names></name><name><surname>Walter</surname><given-names>FM</given-names></name><name><surname>Rubin</surname><given-names>G</given-names></name><name><surname>Neal</surname><given-names>RD</given-names></name></person-group><article-title>Improving early diagnosis of symptomatic cancer</article-title><source>Nat Rev Clin Oncol</source><year>2016</year><volume>13</volume><fpage>740</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.109</pub-id><pub-id pub-id-type="pmid">27458007</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hamilton W, Walter FM, Rubin G, Neal RD (2016) Improving early diagnosis of symptomatic cancer. Nat Rev Clin Oncol 13:740&#x02013;749. 10.1038/nrclinonc.2016.109<pub-id pub-id-type="pmid">27458007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Health Service Executive (2023) Surgical oncology. <ext-link ext-link-type="uri" xlink:href="https://www.hse.ie/eng/services/list/5/cancer/patient/treat/surgery/surgery.html">https://www.hse.ie/eng/services/list/5/cancer/patient/treat/surgery/surgery.html</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Mulcahy Symmons</surname><given-names>S</given-names></name><name><surname>Leavy</surname><given-names>P</given-names></name><name><surname>Heavey</surname><given-names>L</given-names></name><etal/></person-group><article-title>How is equity captured for colorectal, breast and cervical cancer incidence and screening in the Republic of Ireland: a review</article-title><source>Prev Med Rep</source><year>2023</year><volume>36</volume><fpage>102405</fpage><pub-id pub-id-type="doi">10.1016/j.pmedr.2023.102405</pub-id><pub-id pub-id-type="pmid">37753379</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Mulcahy Symmons S, Leavy P, Heavey L et al (2023) How is equity captured for colorectal, breast and cervical cancer incidence and screening in the Republic of Ireland: a review. Prev Med Rep 36. 10.1016/j.pmedr.2023.102405<pub-id pub-id-type="pmid">37753379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y-A</given-names></name><name><surname>Hong</surname><given-names>YT</given-names></name><name><surname>Lin</surname><given-names>XJ</given-names></name><etal/></person-group><article-title>Barriers and facilitators to uptake of lung cancer screening: a mixed methods systematic review</article-title><source>Lung Cancer Amst Neth</source><year>2022</year><volume>172</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2022.07.022</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lin Y-A, Hong YT, Lin XJ et al (2022) Barriers and facilitators to uptake of lung cancer screening: a mixed methods systematic review. Lung Cancer Amst Neth 172:9&#x02013;18. 10.1016/j.lungcan.2022.07.022</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">National Cancer Registry Ireland (2023) NCRI annual statistical report 2023. <ext-link ext-link-type="uri" xlink:href="https://www.ncri.ie/sites/ncri/files/pubs/NCRI_AnnualStatisticalReport_2023.pdf">https://www.ncri.ie/sites/ncri/files/pubs/NCRI_AnnualStatisticalReport_2023.pdf</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Health Service Executive (2019) National cancer survivorship needs assessment: living with and beyond cancer in Ireland. <ext-link ext-link-type="uri" xlink:href="https://www.hse.ie/eng/services/list/5/cancer/profinfo/survivorship-programme/living%20with%20and%20beyond%20cancer%20in%20ireland.pdf">https://www.hse.ie/eng/services/list/5/cancer/profinfo/survivorship-programme/living%20with%20and%20beyond%20cancer%20in%20ireland.pdf</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhael</surname><given-names>PG</given-names></name><name><surname>Wohlwend</surname><given-names>J</given-names></name><name><surname>Yala</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography</article-title><source>J Clin Oncol Off J Am Soc Clin Oncol</source><year>2023</year><volume>41</volume><fpage>2191</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01345</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Mikhael PG, Wohlwend J, Yala A et al (2023) Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography. J Clin Oncol Off J Am Soc Clin Oncol 41:2191&#x02013;2200. 10.1200/JCO.22.01345</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>RD</given-names></name><name><surname>Johnson</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial</article-title><source>Cancers</source><year>2022</year><volume>14</volume><fpage>4818</fpage><pub-id pub-id-type="doi">10.3390/cancers14194818</pub-id><pub-id pub-id-type="pmid">36230741</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Neal RD, Johnson P, Clarke CA et al (2022) Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers 14:4818. 10.3390/cancers14194818<pub-id pub-id-type="pmid">36230741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Health Service Executive (2022) National strategy for accelerating genetic and genomic medicine in Ireland. <ext-link ext-link-type="uri" xlink:href="https://www.hse.ie/eng/about/who/strategic-programmes-office-overview/national-strategy-for-accelerating-genetic-and-genomic-medicine-in-ireland/national-strategy-for-accelerating-genetic-and-genomic-medicine-in-ireland.pdf">https://www.hse.ie/eng/about/who/strategic-programmes-office-overview/national-strategy-for-accelerating-genetic-and-genomic-medicine-in-ireland/national-strategy-for-accelerating-genetic-and-genomic-medicine-in-ireland.pdf</ext-link>. Accessed 8 Jan 2024</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Health Service Executive (2023) Hereditary cancer model of care, HSE National Cancer Control Programme. <ext-link ext-link-type="uri" xlink:href="https://www.hse.ie/eng/services/list/5/cancer/profinfo/hereditary-cancer-genetics/nccp-hereditary-cancer-model-of-care.pdf">https://www.hse.ie/eng/services/list/5/cancer/profinfo/hereditary-cancer-genetics/nccp-hereditary-cancer-model-of-care.pdf</ext-link></mixed-citation></ref></ref-list></back></article>